Age-Related Macular Degeneration Drug Market Size, Share & Trends Analysis Report By Product (Lucentis, Eylea, Avastin, Other), By Applications (Hospitals, Clinics, and Others), By End Use, By Region, and Segment Forecasts - 2035

AGE-RELATED MACULAR DEGENERATION DRUG MARKET REPORT OVERVIEW

age-related macular degeneration drug market size was valued at USD 7665.45 million in 2025 and is poised to grow from USD 8154.51 million in 2026 to USD 15135.78 million by 2035, growing at a CAGR of 6.38% during the forecast period (2026-2035). 

Age-related macular degeneration (AMD) is a circumstance that impacts the most important part of the retina, causing a fake and continuous loss in older people. Drugs for AMD, which include Lucentis, Eylea, and Avastin, are made to slow the spread of the disability and control its symptoms. These medicines, particularly anti-VEGF sellers, help reduce peculiar blood vessel increase and fluid leakage in the retina, which might be the number one reason for the imaginative and prescient deterioration in AMD patients.

• • 

    Download Free sample to learn more about this report.

KEY FINDINGS

• Market Size and Growth: The Age-Related Macular Degeneration Drug Market size was USD 7205.72 Million in 2024, is projected to grow to USD 7945.36 Million by 2025 and exceed USD 13374.72 Million by 2033, with a CAGR of 6.38%.

• Key Market Driver: Over 196 million people globally are living with macular degeneration, and this number is expected to hit 288 million by 2040 — the growing elderly population is clearly driving demand.

• Major Market Restraint: More than 37% of patients discontinue anti-VEGF therapy within the first year due to high treatment burden and frequent clinic visits — it's a frustrating barrier for long-term care.

• Emerging Trends: Biosimilars are stepping into the spotlight — with over 9 biosimilar versions of anti-VEGF drugs in development or early-stage trials across major pharma players.

• Regional Leadership: North America accounts for nearly 42% of global prescriptions, largely thanks to structured reimbursement systems and an aging population that continues to grow.

• Competitive Landscape: Just five pharma giants — including Roche, Novartis, and Regeneron — hold over 75% of the global market share, making it a tightly held space with intense pipeline battles.

• Market Segmentation: Wet AMD continues to dominate, accounting for nearly 68% of total drug-based treatments due to its faster progression and urgent need for intervention.

• Recent Development: In 2024, the FDA approved Izervay™ (avacincaptad pegol) for geographic atrophy — a major breakthrough as it's only the second drug ever approved for late-stage dry AMD.

COVID-19 Impact

"Lockdowns and restrictions led to a decline in patient visits"

The global COVID-19 pandemic has been unprecedented and staggering, with the market experiencing higher-than-anticipated demand across all regions compared to pre-pandemic levels. The sudden market growth reflected by the rise in CAGR is attributable to the market’s growth and demand returning to pre-pandemic levels.

The pandemic disturbed the AMD drug market notably. Lockdowns and restrictions brought about a dull phase in affected person visits to ophthalmologists, impacting the administration of vital remedies like anti-VEGF injections. Additionally, supply chain disruptions impacted the supply of these tablets. However, the scenario also increased the adoption of telemedicine for initial consultations and observe-ups, partly mitigating the effect.

LATEST TRENDS

"Enhanced performance due to the development of long-acting delivery systems"

An extremely good style in the AMD drug market is the development of lengthy-appearing delivery structures and gene treatments. These enhancements intend to reduce the frequency of injections required, thereby improving affected men or women compliance and consequences. Gene remedy, especially, holds promise for offering a greater everlasting approach to handling AMD with the resource of focusing on the underlying genetic causes of the sickness.

• • 

    Download Free sample to learn more about this report.

AGE-RELATED MACULAR DEGENERATION DRUG MARKET SEGMENTATION

By Type

Based on type the market can be categorized into Lucentis, Eylea, Avastin and Other.

• Lucentis: Lucentis (ranibizumab) is an anti-VEGF drug in particular designed for treating moist AMD. It works by inhibiting the growth of unusual blood vessels inside the retina and lowering fluid leakage.

• Eylea: Eylea (aflibercept) is another anti-VEGF medicine used to deal with wet AMD. It functions similarly to Lucentis by blocking off the action of VEGF and, as a consequence stopping extraordinary blood vessel boom and fluid leakage in the retina.

• Avastin: Avastin (bevacizumab), at first advanced for most cancer treatment, is likewise used off-label for moist AMD. It is an anti-VEGF drug that enables lessening the formation of odd blood vessels.

• Other: This category consists of rising treatments and alternative treatments for AMD that aren't as widely recognized or used as Lucentis, Eylea, and Avastin. It may additionally encompass more modern anti-VEGF drugs, gene remedies, and different modern approaches currently underneath development or within the early ranges of market access.

By Application

Based on application the market can be categorized into Hospitals, Clinics, and Others.

• Hospitals: Hospitals play a crucial function in the management and management of AMD remedies.

• Clinics: Clinics, along with specialised eye clinics and outpatient facilities, are pivotal in imparting accessible AMD treatment. They frequently cope with the recurring administration of anti-VEGF injections and other treatments, offering handy and non-stop care for AMD patients.

• Others: This section includes Opportunity healthcare settings along with studies establishments, domestic healthcare services, and other specialised facilities that contribute to AMD remedy.

Driving Factors

"Increased demand due to the rising number of elderly individuals globally and"

The rising variety of aged people globally is a number one driver for the AMD drug marketplace. As the population has a long time, the incidence of age-associated macular degeneration increases, leading to more demand for powerful treatments. Improved existence expectancy and getting older demographics, mainly in evolved areas like North America and Europe, have considerably contributed to the growing affected person pool requiring AMD medicinal drugs.

"Continuous advancements in biotechnology boost market growth"

Continuous improvements in biotechnology and pharmaceutical research are using the development of innovative remedies for AMD. The advent of new drug formulations, such as lengthy-acting anti-VEGF sellers and gene treatment plans, enhances treatment efficacy and affects person compliance. These technological improvements, supported by strong studies and improvement efforts, are increasing the healing alternatives to be had, thereby boosting the Age-Related Macular Degeneration Drug Market growth.

Restraining Factor

"Challenges due to the high cost of treatment"

One foremost restraining thing within the AMD drug marketplace is the high cost of remedy. Anti-VEGF capsules, at the same time as powerful, are high priced and require common administration, making them much less handy to patients without good enough coverage insurance or the ones in low-profit regions. This monetary barrier limits the great adoption of these remedies.

• • 

    Download Free sampleto learn more about this report.

•  

AGE-RELATED MACULAR DEGENERATION DRUG MARKET REGIONAL INSIGHTS

The market is primarily segregated into Europe, Latin America, Asia Pacific, North America, and Middle East & Africa.

"North America dominates the market primarily due to its advanced healthcare infrastructure"

North America dominates the Age-Related Macular Degeneration Drug Market share, via and massive, due to its superior healthcare infrastructure, excessive incidence of AMD, and strong presence of key pharmaceutical agencies. The vicinity's properly hooked up healthcare policies and awesome funding in studies and improvement additionally contribute to its leading role in the market.

KEY INDUSTRY PLAYERS

"Key Players changed the Age-Related Macular Degeneration Drug Landscape through Innovation "

Key gamers inside the AMD drug marketplace play a vital role via investing in research and development to convey revolutionary remedies to the market. They also engage in strategic partnerships, scientific trials, and regulatory approvals to make their product portfolios and geographical attain. Additionally, these companies often lead instructional tasks to elevate consciousness about AMD and the significance of early detection and treatment.

List of Market Players Profiled

• Roche (Genentech) (Switzerland)
• Novartis (Switzerland)
• Regeneron Pharmaceuticals (U.S.A.)
• Bayer AG (Germany)
• Biogen (U.S.A.)

INDUSTRIAL DEVELOPMENT

November 2024: Regeneron Pharmaceuticals announced the FDA approval of Eylea HD, better-dose components in their blockbuster drug Eylea, designed to increase the period between injections for AMD patients. This development objective is to improve patient adherence and comfort even while maintaining the efficacy of the remedy.

REPORT COVERAGE

This report is based on historical analysis and forecast calculation that aims to help readers get a comprehensive understanding of the global Age Related Macular Degeneration Drug market from multiple angles, which also provides sufficient support to readers’ strategy and decision-making. Also, this study comprises a comprehensive analysis of SWOT and provides insights for future developments within the market. It examines varied factors that contribute to the growth of the market by discovering the dynamic categories and potential areas of innovation whose applications may influence its trajectory in the upcoming years. This analysis encompasses both recent trends and historical turning points into consideration, providing a holistic understanding of the market’s competitors and identifying capable areas for growth.

This research report examines the segmentation of the market by using both quantitative and qualitative methods to provide a thorough analysis that also evaluates the influence of strategic and financial perspectives on the market. Additionally, the report's regional assessments consider the dominant supply and demand forces that impact market growth. The competitive landscape is detailed meticulously, including shares of significant market competitors. The report incorporates unconventional research techniques, methodologies and key strategies tailored for the anticipated frame of time. Overall, it offers valuable and comprehensive insights into the market dynamics professionally and understandably.